Do QT - Search Results

1

Topological analysis of the complex formed between neurokinin A and the NK2 tachykinin receptor.

Zoffmann S, Bertrand S, Do QT, Bertrand D, Rognan D, Hibert M, Galzi JL. Zoffmann S, et al. Among authors: do qt. J Neurochem. 2007 Apr;101(2):506-16. doi: 10.1111/j.1471-4159.2007.04473.x. J Neurochem. 2007. PMID: 17402972 Free article.

2

A strategy to discover decoy chemokine ligands with an anti-inflammatory activity.

Abboud D, Daubeuf F, Do QT, Utard V, Villa P, Haiech J, Bonnet D, Hibert M, Bernard P, Galzi JL, Frossard N. Abboud D, et al. Among authors: do qt. Sci Rep. 2015 Oct 7;5:14746. doi: 10.1038/srep14746. Sci Rep. 2015. PMID: 26442456 Free PMC article.

3

Randomized double-blind placebo-controlled cosmetic trial of a topical first-in-class Neutraligand targeting the chemokine TARC/CCL17 in mild-to-moderate atopic dermatitis.

Frossard N, Coïc A, Saguet T, Coïc A, Himbert F, Do QT, Galzi JL, Suehs C, Guillaumet G, Bonnet P, Bernard P. Frossard N, et al. Among authors: do qt. Int J Cosmet Sci. 2024 Jun;46(3):468-477. doi: 10.1111/ics.12948. Epub 2024 Feb 7. Int J Cosmet Sci. 2024. PMID: 38326978 Clinical Trial.

4

Mapping the active site of factor Xa by selective inhibitors: an NMR and MD study.

Fraternali F, Do QT, Doan BT, Atkinson RA, Palmas P, Sklenar V, Safar P, Wildgoose P, Strop P, Saudek V. Fraternali F, et al. Among authors: do qt. Proteins. 1998 Feb 15;30(3):264-74. doi: 10.1002/(sici)1097-0134(19980215)30:3<264::aid-prot6>3.0.co;2-k. Proteins. 1998. PMID: 9517542

5

Pharmacognosy and reverse pharmacognosy: a new concept for accelerating natural drug discovery.

Do QT, Bernard P. Do QT, et al. IDrugs. 2004 Nov;7(11):1017-27. IDrugs. 2004. PMID: 15551177 Review.

6

Optimization and validation of a docking-scoring protocol; application to virtual screening for COX-2 inhibitors.

Mozziconacci JC, Arnoult E, Bernard P, Do QT, Marot C, Morin-Allory L. Mozziconacci JC, et al. Among authors: do qt. J Med Chem. 2005 Feb 24;48(4):1055-68. doi: 10.1021/jm049332v. J Med Chem. 2005. PMID: 15715473

7

Reverse pharmacognosy: application of selnergy, a new tool for lead discovery. The example of epsilon-viniferin.

Do QT, Renimel I, Andre P, Lugnier C, Muller CD, Bernard P. Do QT, et al. Curr Drug Discov Technol. 2005 Sep;2(3):161-7. doi: 10.2174/1570163054866873. Curr Drug Discov Technol. 2005. PMID: 16472225

8

Cyclic nucleotide phosphodiesterase type 4 inhibitors: evaluation of pyrazolo[1,5-a]-1,3,5-triazine ring system as an adenine bioisostere.

Raboisson P, Schultz D, Muller C, Reimund JM, Pinna G, Mathieu R, Bernard P, Do QT, Desjarlais RL, Justiano H, Lugnier C, Bourguignon JJ. Raboisson P, et al. Among authors: do qt. Eur J Med Chem. 2008 Apr;43(4):816-29. doi: 10.1016/j.ejmech.2007.05.016. Epub 2007 Jun 8. Eur J Med Chem. 2008. PMID: 17640774

9

Reverse pharmacognosy: identifying biological properties for plants by means of their molecule constituents: application to meranzin.

Do QT, Lamy C, Renimel I, Sauvan N, André P, Himbert F, Morin-Allory L, Bernard P. Do QT, et al. Planta Med. 2007 Oct;73(12):1235-40. doi: 10.1055/s-2007-990216. Epub 2007 Sep 13. Planta Med. 2007. PMID: 17853346

10

Indolobenzazepin-7-ones and 6-, 8-, and 9-membered ring derivatives as tubulin polymerization inhibitors: synthesis and structure--activity relationship studies.

Putey A, Popowycz F, Do QT, Bernard P, Talapatra SK, Kozielski F, Galmarini CM, Joseph B. Putey A, et al. Among authors: do qt. J Med Chem. 2009 Oct 8;52(19):5916-25. doi: 10.1021/jm900476c. J Med Chem. 2009. PMID: 19743863

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters